Worth reading
65In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
959
¥ million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending March 20279 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥9,754 million+10.9%
Operating profit¥1,242 million+1.6%
Ordinary income¥1,176 million+2.4%
Net income¥1,094 million +32.1%profit attributable to owners of the parent
Operating profit margin12.7%, up 0.2 percentage points year on year
Results for the three months of the current quarterRevenue: ¥9,754 million; operating income: ¥1,242 million; ordinary income: ¥1,176 million; quarterly net income attributable to owners of the parent: ¥1,094 million
Full-year earnings forecast
Net Sales
¥39,100 million
Operating profit
¥4,800 million
Ordinary income
¥4,900 million
Profit attributable to owners of the parent
¥3,400 million
Earnings per share
¥278.55
Annual Dividend
¥180 per share
Capital expenditures
¥4,600 million
Depreciation and amortization
¥3,150 million
Research and development costs
¥820 million
ROE
7 %
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Sales volume¥300 million
- Price¥-350 million
- Other (High-Purity Chemicals business)¥-45 million
- Other businesses and eliminations¥115 million
New initiatives
- Completed development of a highly selective etching solution with greater selectivity than existing products and conducted sample work for users
- Expanded public-relations activities and sample work ahead of the full-scale launch of cell culture vessels, with initiatives targeting sales in fiscal 2027
- Expanded synthesis applications for high-value-added organofluorine compounds
- Developed a coating material for cathode active materials used in lithium-ion secondary batteries, targeting commercialization for all-solid-state batteries around 2030
- Decision to repurchase own shares
Key KPIsA metric the company considers important as a management benchmark.
- High-purity hydrofluoric acid (semiconductors) shipment volume18,700 t
- Overseas sales ratio of semiconductor revenue56.1 %
- Average import trade price of hydrofluoric acid from China in the first quarter of the fiscal year ending March 2027384 Yen/kg
Segment results
High-purity chemicals
Net Sales
¥8,383 million+10.2%
Operating profit
¥902 million-9.6%
Transportation
Net Sales
¥1,350 million+16.5%
Operating profit
¥337 million+48.8%
Other
Net Sales
¥20 million-23.4%
Operating profit
¥3 million+65.0%
Financial targets
Full-year ROE forecast of 7.0% (6.6% actual for the fiscal year ended March 2026)Capital expenditures
¥486 million
Annual Dividend
Forecast annual dividend of ¥180 per share for the fiscal year ending March 2027 (interim: ¥90; year-end: ¥90)Payout ratio
Total payout ratio: target of at least 100% cumulatively over the 3-year period from the fiscal year ended March 2026 through the fiscal year ending March 2028Acquisition of treasury shares
Up to 300,000 shares and ¥1.9 billion. Acquisition period: 7 August 2026 to 30 October 2026| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending March 2027 |
| Net Sales | ¥9,754 million (YoY +10.9%) |
| Operating profit | ¥1,242 million (YoY +1.6%) |
| Ordinary income | ¥1,176 million (YoY +2.4%) |
| Net income | ¥1,094 million (profit attributable to owners of the parent) (YoY +32.1%) |
| Operating profit margin | 12.7%, up 0.2 percentage points year on year |
| Results for the three months of the current quarter | Revenue: ¥9,754 million; operating income: ¥1,242 million; ordinary income: ¥1,176 million; quarterly net income attributable to owners of the parent: ¥1,094 million |
| Full-year earnings forecast | Net Sales ¥39,100 million / Operating profit ¥4,800 million / Ordinary income ¥4,900 million / Profit attributable to owners of the parent ¥3,400 million / Earnings per share ¥278.55 / Annual Dividend ¥180 per share / Capital expenditures ¥4,600 million / Depreciation and amortization ¥3,150 million / Research and development costs ¥820 million / ROE 7 % |
| Segment results | High-purity chemicals Net Sales ¥8,383 million (YoY +10.2%) / Operating profit ¥902 million (YoY -9.6%) / Transportation Net Sales ¥1,350 million (YoY +16.5%) / Operating profit ¥337 million (YoY +48.8%) / Other Net Sales ¥20 million (YoY -23.4%) / Operating profit ¥3 million (YoY +65.0%) |
| Breakdown of Factors Affecting the Change | Factors Sales volume / Amount ¥300 million, Factors Price / Amount ¥-350 million, Factors Other (High-Purity Chemicals business) / Amount ¥-45 million, Factors Other businesses and eliminations / Amount ¥115 million |
| Key KPIs | Indicator name High-purity hydrofluoric acid (semiconductors) shipment volume / Value 18,700 t / Year on year against the same period last year Not disclosed, Indicator name Overseas sales ratio of semiconductor revenue / Value 56.1 % / Year on year against the same period last year Not disclosed, Indicator name Average import trade price of hydrofluoric acid from China in the first quarter of the fiscal year ending March 2027 / Value 384 Yen/kg / Year on year against the same period last year Not disclosed |
| Financial targets | Full-year ROE forecast of 7.0% (6.6% actual for the fiscal year ended March 2026) |
| Annual Dividend | Forecast annual dividend of ¥180 per share for the fiscal year ending March 2027 (interim: ¥90; year-end: ¥90) |
| Payout ratio | Total payout ratio: target of at least 100% cumulatively over the 3-year period from the fiscal year ended March 2026 through the fiscal year ending March 2028 |
| Acquisition of treasury shares | Up to 300,000 shares and ¥1.9 billion. Acquisition period: 7 August 2026 to 30 October 2026 |
| Capital expenditures | ¥486 million |
| New initiatives | Completed development of a highly selective etching solution with greater selectivity than existing products and conducted sample work for users, Expanded public-relations activities and sample work ahead of the full-scale launch of cell culture vessels, with initiatives targeting sales in fiscal 2027, Expanded synthesis applications for high-value-added organofluorine compounds, Developed a coating material for cathode active materials used in lithium-ion secondary batteries, targeting commercialization for all-solid-state batteries around 2030, Decision to repurchase own shares |
Items this document does not state (13)
Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to higher selling prices in the Semiconductor segment and increased shipment volumes in the Electronic Materials segment and other businesses. Operating income was affected by higher raw material prices and increased costs, but rose on higher selling prices, increased freight-handling volumes in the Transportation business and improved profitability. Net income included a gain on changes in equity interests associated with a capital increase by a domestic affiliate. The full-year forecast was left unchanged because, although higher raw material prices and other factors are expected to increase costs, selling prices have been raised and shipments in the Semiconductor and Electronic Materials segments remain firm.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.